Jeremy G. Chadwick, Chief Operating Officer at Kymera Therapeutics, Inc. (KYMR), sold 230,754 shares at $76.73 ($18.0M) on 2026-03-23, disclosed to the SEC on 2026-03-25.
Scheduled sale ($18.0M) by Chief Operating Officer under a pre-arranged 10b5-1 plan. Pre-set trade — not a discretionary signal on the stock.
Nothing distinguishes this filing.
| # | Price | Shares | Value | % of Total |
|---|---|---|---|---|
| 1 | $76.73 | 22,756 | $1.7M | 9.7% |
| 2 | $76.73 | 22,756 | $1.7M | 9.7% |
| 3 | $77.21 | 52,975 | $4.1M | 22.7% |
| 4 | $77.21 | 52,975 | $4.1M | 22.7% |
| 5 | $78.40 | 8,214 | $644K | 3.6% |
| 6 | $78.40 | 8,214 |
| $644K |
| 3.6% |
| 7 | $79.87 | 6,105 | $488K | 2.7% |
| 8 | $79.87 | 6,105 | $488K | 2.7% |
| 9 | $80.05 | 1,200 | $96K | 0.5% |
| 10 | $80.26 | 24,727 | $2.0M | 11.0% |
| 11 | $80.26 | 24,727 | $2.0M | 11.0% |
| Total | $78.01 avg | 230,754 | $18.0M | 100% |
| Filing → |
| KYMR | SELL | 2026-04-16 | $590K | — | Filing → |
| KYMR | SELL | 2026-04-01 | $1.9M | — | Filing → |
| KYMR | SELL | 2026-03-11 | $4.3M | — | Filing → |